AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$KZIA

KAZIA THERAPEUTICS LTD

Price · $KZIAvia TradingView
AI sentiment · 7d5 articles
MAY 22net (bullish − bearish)MAY 28
Bullish
5
Neutral
0
Bearish
0
Insider · 30dFeed →

No SEC Form 4 filings for $KZIA in the last 30 days.

Top stories · $KZIAMore →
MAY 27·fnarena.comMed

Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer

Kazia Therapeutics (NASDAQ: KZIA) said it will expand its ongoing Phase 1b trial of paxalisib plus standard-of-care therapy in advanced triple-negative breast cancer. The company plans to increase enrollment from 12 to 36 patients, citing continued safety, tolerability and early clinical activity. It aims to further assess dose optimization and preliminary efficacy with pembrolizumab and chemotherapy, and expects updates through 2026–2027.

MAY 26·australiannews.net

Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer

Kazia Therapeutics (NASDAQ: KZIA) said it will expand its ongoing Phase 1b trial of paxalisib plus standard-of-care therapy in advanced triple-negative breast cancer. Planned enrollment will rise from 12 to 36 patients, based on continued safety, tolerability and early clinical activity. The larger dataset is expected to better assess ORR, PFS and biomarkers, with updates anticipated through 2026–2027.

MAY 26·singaporestar.com

Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer

Kazia Therapeutics (NASDAQ: KZIA) said it will expand its ongoing Phase 1b trial of paxalisib plus standard-of-care in advanced triple-negative breast cancer, increasing planned enrollment from 12 to 36 patients. The company cited continued safety, tolerability and early clinical activity, aiming to better assess ORR, PFS and biomarkers with pembrolizumab and chemotherapy.

News on $KZIA